Cargando…
Are mGluR2/3 Inhibitors Potential Compounds for Novel Antidepressants?
Depression is the most common mental illness characterized by anhedonia, avolition and loss of appetite and motivation. The majority of conventional antidepressants are monoaminergic system selective inhibitors, yet the efficacies are not sufficient. Up to 30% of depressed patients are resistant to...
Autores principales: | Jiang, Yajie, Zou, Manshu, Ren, Tingting, Wang, Yuhong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10287579/ https://www.ncbi.nlm.nih.gov/pubmed/36443586 http://dx.doi.org/10.1007/s10571-022-01310-8 |
Ejemplares similares
-
The Changes in mGluR2 and mGluR7 Expression in Rat Medial Vestibular Nucleus and Flocculus Following Unilateral Labyrinthectomy
por: Zhou, Wen, et al.
Publicado: (2013) -
Group I mGluRs in Therapy and Diagnosis of Parkinson’s Disease: Focus on mGluR5 Subtype
por: Azam, Shofiul, et al.
Publicado: (2022) -
Investigating the role of mGluR2 versus mGluR3 in antipsychotic-like effects, sleep-wake architecture and network oscillatory activity using novel Han Wistar rats lacking mGluR2 expression
por: Wood, Christian M., et al.
Publicado: (2018) -
Therapeutic potential of mGluR5 targeting in Alzheimer's disease
por: Kumar, Anil, et al.
Publicado: (2015) -
mGluR5, CB1 and neuroprotection
por: Carvalho, Toniana G., et al.
Publicado: (2016)